ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M...

|By:, SA News Editor

ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M (+6% Y/Y) and -$0.11, below a consensus of  $41.9M and $0.05. Perhaps more importantly, ISTA is also reporting that a a Phase 3 study for its REMURA drug for treating dry eye disease showed that the drug "was not statistically significantly better" than a placebo.